KHRNF - Khiron Life Sciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.9600
+0.0458 (+5.01%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.9142
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume297,952
Market Cap73.167M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Khiron Life Sciences Completes Acquisition of ILANS

    TORONTO, Dec. 13, 2018 -- Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with.

  • CNW Group8 days ago

    Khiron Life Sciences Receives Endorsement from Prominent Colombian Medical Association for the Study of Pain

    TORONTO, Dec. 11, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce it has signed an endorsement agreement with the highly respected and influential Colombian Association for the Study of Pain (ACED). In endorsing Khiron's patient-focused approach to medical cannabis research and product development, ACED has committed to partnering with the Company on a schedule of patient and physician education programs, modules and events.

  • CNW Group16 days ago

    Khiron Life Sciences Enters Mexican Cannabis Market With The Launch of Its First Nutraceutical Product Line

    TORONTO, Dec. 3, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that its wholly-owned subsidiary, Kuida Life Mexico S.A., has received approval from Mexico's Federal Commission for the Protection against Sanitary Risk  (COFEPRIS) to import and commercialize three products of the Company's Nutraceutical Line. The commencement of sales in Mexico is subject to prior TSX Venture Exchange ("TSXV") approval.

  • GlobeNewswire20 days ago

    Khiron Life Sciences Reports Third Quarter Fiscal 2018 Financial Results

    Khiron Life Sciences Corp. (“Khiron” or the “Company”) (KHRN.V) (KHRNF) (Frankfurt:A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today its financial results for the third quarter ended September 30, 2018. Appointed Mr. Vicente Fox to the Khiron Board of Directors. Mr. Fox is the former CEO of Coca Cola Mexico, former President of Mexico and a significant advocate for the legalization of cannabis in Mexico.

  • GlobeNewswire20 days ago

    Breaking News: Passage of 2018 Farm Bill could open cannabis cosmetics industry to players like Aurora Cannabis, Khiron Life Sciences, American Premium Water Corp, and LVMH’s Sephora

    The 2018 Farm Bill is “very close to passing” according to Collin Peterson, Rep D-Minnesota, and added with the recent legalization in Canada, there has been a focus on companies in the recreational and medical cannabis sector. With the growing spotlight on CBD oil use for medical purposes, it may be surprising to learn that CBD is being used in beauty products as well. Scientists are discovering that CBD oil has many other uses, other than for medical purposes, and when it comes to beauty products it may be the most natural product you can use.

  • CNW Group22 days ago

    Khiron Life Sciences Enters Peruvian Cannabis Market With Approval For Commercialization Of Kuida® CBD Cosmeceutical Brand

    TORONTO, Nov. 27, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has received approval to commercialize and market four key products in the Company's Kuida® CBD cosmeceutical product line in Peru. This approval, from Peru's Executive Director of the Directorate of Medical Devices and Health Products of the General Directorate of Medications, Supplies and Drugs (DIGEMID) brings Kuida® product to a population of 32 Million people in Peru, and with previously announced agreements in Colombia and Mexico, positions the Kuida® brand to now be marketed to a combined population of almost 200 Million in Latin America.

  • CNW Grouplast month

    Khiron Life Sciences Achieves Milestone With Additional Cultivation Quotas From The Colombian Technical Quotas Group

    TORONTO, Nov. 19, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce that it has received additional quotas from the Colombian Technical Quotas Group ("TQG"), to cultivate 5,040 psychoactive cannabis plants for the purposes of completing the Colombian Agricultural Institute ("ICA") agronomic evaluation tests. This represents a key milestone towards Khiron's stated timeline to bring medical cannabis options to market in Colombia.

  • CNW Grouplast month

    Khiron Life Sciences Announces Completion of Warrant Acceleration

    TORONTO, Nov. 15, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce that the Company has received  $14,007,000 from the exercise of warrants of which the expiry date was accelerated to November 14, 2018 (the "Warrants"), as previously announced on October 25, 2018. Khiron Life Sciences Corp.  (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) ("Khiron" or the "Company") is positioned to be the dominant integrated medical cannabis company in Latin America.

  • CNW Grouplast month

    Khiron Life Sciences Welcomes Cannabis Legislation Proposed by Incoming Government of Mexico

    TORONTO, Nov. 8, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, welcomes the initiative presented today by the incoming Government of Mexico through its next secretary of the Interior, Dr. Olga Sánchez Cordero, for the Regulation and Control of Cannabis in Mexico. The General Law for the Regulation and Control of Cannabis, presented by Dr. Olga Sanchez will establish Mexico among Latin American countries that have legislated the use of cannabis for recreational, medical, scientific, research, industrial and commercial purposes.  Mexico has the second largest population in Latin America and 11.7 million potential patients for medical cannabis.

  • CNW Grouplast month

    Khiron Life Sciences Announces Mexican Retail Distribution for Kuida® CBD Cosmeceutical Brand

    TORONTO, Nov. 6, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has extended an agreement with Farmalisto, the regions leading digital drugstore, to market and distribute the Company's Kuida® CBD cosmeceutical brand to a population of over 120 million consumers in Mexico, subject to approvals from the Federal Commission for the Protection of Health Risks (COFEPRIS).

  • CNW Grouplast month

    Khiron Life Sciences Applauds Government of Mexico on Announcing Guidelines for the Production and Import of Medical Cannabis Products

    TORONTO, Nov. 5, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, applauds today's announcement by the Government of Mexico establishing guidelines for the sanitary control of cannabis and its extracts. In today's announcement made by Mr. Julio Sánchez y Tepóz, Federal Commissioner of COFEPRIS, the commission laid out the key components of the provision, medical and scientific research and types of cannabis products. Former Mexican President and Khiron board member Mr. Vicente Fox stated, "With today's announcement we are gradually seeing the move towards a much-needed framework for legalized cannabis in Mexico.

  • CNW Group2 months ago

    Khiron Secures Endorsement from the Leading Palliative Care Association in Colombia

    TORONTO, Oct. 26, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has signed an exclusive agreement with the Colombian Association of Palliative Care (ACCP), the leading network of pain and palliative care specialists in Colombia.

  • CNW Group2 months ago

    Khiron Life Sciences Announces Acceleration of Expiry Date of Warrants

    TORONTO, Oct. 25, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN, OTCQB: KHRNF, Frankfurt: A2JMZC), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to announce that the Company has elected to exercise its right under the warrant indenture (the "Indenture") governing the common share purchase warrants of the Company (the "Warrants") issued on January 12, 2018. Pursuant to the terms of the Indenture, the Company may accelerate the expiry date of the Warrants when the closing price of the common shares of the Company (the "Common Shares") on the TSX Venture Exchange exceeds $1.40 for a period of 10 consecutive trading days in any 30 trading day period (the "Acceleration Event").

  • CNW Group2 months ago

    Khiron Life Sciences Announces Launch of Khiron Clinics With the Signing of the Definitive Agreement to Acquire ILANS

    Acquisition of ILANS, with 100,000 patients, a first step towards creating the leading clinic network in Latin America TORONTO , Oct. 24, 2018 /CNW/ - Khiron Life Sciences Corp. (" Khiron " or ...

  • CNW Group3 months ago

    Khiron Life Sciences Corp. Announces Colombian Retail Distribution Partners for Kuida® CBD Cosmeceutical Brand

    TORONTO, Oct. 2, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that it has signed multi-channel distribution agreements for Kuida®, its first CBD-based skincare brand. As part of a robust strategy, Kuida® launches with secured distributor agreements that leverage their market reach, geographic location, scale and ability to ensure the Kuida® brand achieves its market potential.

  • CNW Group3 months ago

    Khiron Life Sciences Corp. Announces Formation of Wellness Business Unit and the Launch of Its First CBD Cosmeceutical Brand

    TORONTO, Sept. 28, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN) (OTCQB:KHRNF - News) (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today the creation of Khiron Wellness, and the launch of Kuida®, its first CBD-based skincare brand. With this achievement, Kuida® becomes the first mass-market CBD-based brand approved by INVIMA, Colombia´s health agency, and available for sale in Colombia. Khiron's Wellness business unit is focused on cosmeceutical and nutraceutical products, offering the full benefits of cannabis to consumers across Latin America.

  • CNW Group3 months ago

    Khiron Life Sciences Signs Non-Binding MOU to Enter Chilean Medical Cannabis Market with Country's Only Licensed Producer, Fundacion Daya and DayaCann

    TORONTO, Sept. 27, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN) (OTCQB:KHRNF - News) (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has signed a non-binding memorandum of understanding with Fundacion Daya, Chile's leading medical cannabis institution and the holder of Chile's only medical cannabis license through DayaCann, a joint venture entity established between Fundacion Daya and AusCann Group Holdings Ltd.

  • CNW Group3 months ago

    Khiron Life Sciences Announces Incorporation into Horizons Emerging Marijuana Growers Index ETF

    TORONTO , Sept. 26, 2018 /CNW/ - Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN, OTCQB: KHRNF, Frankfurt : A2JMZC), an integrated medical cannabis company with ...

  • CNW Group3 months ago

    Khiron Life Sciences Director and Former President of Mexico, Mr. Vicente Fox to Present Keynote Address at Global Cannabis Business Conference in Jamaica

    Conference to offer insight on global medicinal, health, regulatory, business and investment landscape TORONTO , Sept. 26, 2018 /CNW/ - Khiron Life Sciences Corp. (" Khiron " or the " Company ...

  • CNW Group3 months ago

    Khiron Life Sciences Corp. to Present at Virtual Investor Conference

    Live Webcast Scheduled for September 12, 2018 , 2:00pm EDT , followed by Q&A TORONTO , Sept. 12, 2018 /CNW/ --  KHIRON LIFE SCIENCES CORP. ("Khiron" or the "Company") (TSXV: KHRN, OTCQB: ...

  • CNW Group3 months ago

    Khiron announces closing of $12.93 million prospectus financing including full exercise of over-allotment option

    TORONTO, Sept. 12, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to announce that it has closed today its previously announced best efforts short form prospectus offering of common shares ("Common Shares"), including the exercise in full of the over-allotment option (the "Offering"). A total of 14,375,000 Common Shares were sold at a price of $0.90 per Common Share (the "Issue Price") for aggregate gross proceeds of $12,937,500 (including the exercise in full of the over-allotment option).

  • CNW Group3 months ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present September 12

    Cannabis company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Sept. 6, 2018 /CNW/ -- VirtualinvestorConferences.com and KCSA Strategic Communications today ...

  • CNW Group4 months ago

    Khiron Announces Pricing of Marketed Short Form Prospectus Offering of Common Shares

    TORONTO, Aug. 23, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN , OTCQB:KHRNF), a Canadian integrated medical cannabis company with its core operations in Colombia, is pleased to report that it has priced and sized its previously announced marketed offering of common shares at a price of $0.90 per share to raise aggregate gross proceeds of up to $11,250,000 (the "Offering"). The Offering will be conducted through a syndicate of agents on a best efforts basis led by Canaccord Genuity Corp., and including GMP Securities L.P., Sprott Private Wealth LP, and Cormark Securities Inc. (together, the "Agents").  The Company has also granted the Agents with an over-allotment option to offer and sell up to an additional 15% of the number of common shares sold in the Offering.

  • CNW Group4 months ago

    Khiron lists on OTCQB Venture Market

    TORONTO , Aug. 15, 2018 /CNW/ - Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQB: KHRNF), a Canadian integrated medical cannabis company with its core ...